BioNTech SE Return on Equity (ROE) Growth & History (BNTX)
BioNTech SE's return on equity was −5.88% for fiscal 2025.
View full BioNTech SE company overviewBioNTech SE annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −5.88% | −2.53 pp |
| 2024 | 2024-12-31 | −3.36% | −7.97 pp |
| 2023 | 2023-12-31 | 4.62% | −54.44 pp |
| 2022 | 2022-12-31 | 59.06% | −96.12 pp |
| 2021 | 2021-12-31 | 155.18% | +153.55 pp |
| 2020 | 2020-12-31 | 1.63% | +48.81 pp |
| 2019 | 2019-12-31 | −47.18% | −2.89 pp |
| 2018 | 2018-12-31 | −44.29% | — |
BioNTech SE quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −4.50% | −2.46 pp |
| Q1 2026 | 2026-03-31 | −2.81% | — |
| Q4 2025 | 2025-12-31 | −1.62% | — |
| Q3 2025 | 2025-09-30 | −0.16% | — |
| Q2 2025 | 2025-06-30 | −2.04% | — |
BioNTech SE return on equity trends
Over the last five fiscal years, BioNTech SE's return on equity decreased from 1.63% to −5.88%, a change of −7.51 percentage points. The latest reported quarter, Q2 2026, shows −4.50%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BioNTech SE source filings ↗